Antithrombin deficiency in special clinical syndromes--Part II: panel discussion #2.
Sacher
R
R
D000925:Anticoagulants / Q000494:pharmacology / Q000627:therapeutic use; D000990:Antithrombin III / Q000008:administration & dosage / Q000032:analysis / Q000627:therapeutic use; D020152:Antithrombin III Deficiency; D001780:Blood Coagulation Tests; D002315:Cardiopulmonary Bypass / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000209:etiology / Q000503:physiopathology; D004211:Disseminated Intravascular Coagulation / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D004730:Endothelium, Vascular / Q000503:physiopathology; D016027:Heart Transplantation / Q000009:adverse effects; D006493:Heparin / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009102:Multiple Organ Failure / Q000097:blood / Q000150:complications; D009131:Muscle, Smooth, Vascular / Q000503:physiopathology; D010446:Peptide Fragments / Q000032:analysis; D010447:Peptide Hydrolases / Q000032:analysis; D011516:Prothrombin / Q000032:analysis; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control
D000925:Anticoagulants; D010446:Peptide Fragments; C046193:antithrombin III-protease complex; C045879:prothrombin fragment 1.2; D000990:Antithrombin III; D011516:Prothrombin; D006493:Heparin; D010447:Peptide Hydrolases